表皮生长因子受体酪氨酸激酶抑制剂与非小细胞肺癌的治疗  

EGFR-TKI in non-small cell lung cancer treatment

作　　者：郑伟慧[1] 毛伟敏[1] 

机构地区：[1]浙江省肿瘤医院胸部肿瘤中心重点实验室,杭州310022

出　　处：《国际肿瘤学杂志》2012年第8期601-604,共4页Journal of International Oncology

摘　　要：表皮生长因子受体酪氨酸激酶抑制剂（EGFR—TKI）是一类高效低毒的抗肿瘤分子靶向药物，因其独特的疗效和良好的耐受性在非小细胞肺癌（NSCLC）治疗中成为研究的热点，在NSCLC的一线、二线或三线的辅助治疗中均有一定地位。随着研究的深入细化，EGFR—TKI的适应证不断扩大，术前新辅助治疗可能成为一种新的治疗模式。The epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） is a kind of high-efficiency and low-toxicity tumor molecular targeted drugs. It becomes a research hotspot in non-small cell lung cancer （NSCLC） treatment because of its unique curative effect and well tolerance. EGFR-TKI is mainly applied to the second and third line treatment of patients with advanced NSCLC or first line treatment of EGFR mutation patients. With the development of research, the indications of EGFR-TKI expand unceasingly. The preoperative neoadjuvant therapy is likely to become a new kind of treatment mode.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]